financetom
Business
financetom
/
Business
/
CAE Fiscal Q2 Adjusted Earnings Fall, Revenue Rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CAE Fiscal Q2 Adjusted Earnings Fall, Revenue Rises
Nov 11, 2025 1:56 PM

04:23 PM EST, 11/11/2025 (MT Newswires) -- CAE (CAE) reported fiscal Q2 adjusted earnings late Tuesday of CA$0.23 ($0.16), down from CA$0.24 a year earlier.

Analysts polled by FactSet expected CA$0.20.

Revenue for the quarter ended Sept. 30 was CA$1.24 billion, up from CA$1.14 billion a year earlier.

Analysts surveyed by FactSet expected CA$1.14 billion.

Shares of the company were up over 2% during after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
STMicroelectronics to Build Italy Silicon Carbide Factory With Government Support
STMicroelectronics to Build Italy Silicon Carbide Factory With Government Support
May 31, 2024
04:20 AM EDT, 05/31/2024 (MT Newswires) -- STMicroelectronics ( STM ) said Friday it plans to build the world's first fully integrated silicon carbide facility in Catania, Italy. The 5 billion euros ($5.41 billion) factory, which includes 2 billion euros in support by the government of Italy, will produce up to 15,000 200mm silicon carbide wafers for various semiconductors per...
Orrstown Financial Services, Codorus Valley Bancorp Merger Gets Shareholder Approval
Orrstown Financial Services, Codorus Valley Bancorp Merger Gets Shareholder Approval
May 31, 2024
04:32 AM EDT, 05/31/2024 (MT Newswires) -- Orrstown Financial Services ( ORRF ) and Codorus Valley Bancorp ( CVLY ) said late Thursday both companies have received shareholder approval for their planned merger. Orrstown shareholders also approved the issuance of shares of Orrstown common stock to Codorus Valley shareholders. The merger will likely close in Q3. ...
AbbVie Receives European Medicine Agency Committee's Recommendation for Approval of Severe Bowel Disease Drug Candidate
AbbVie Receives European Medicine Agency Committee's Recommendation for Approval of Severe Bowel Disease Drug Candidate
May 31, 2024
04:35 AM EDT, 05/31/2024 (MT Newswires) -- AbbVie ( ABBV ) said Friday that the European Medicines Agency's advisory committee recommended approval of risankizumab for treating adults with moderately to severely active ulcerative colitis who have not responded adequately to conventional or biologic therapy. The Committee for Medical Products for Human Use's recommendation was based on two phase 2 trials,...
Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy
Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy
May 31, 2024
04:28 AM EDT, 05/31/2024 (MT Newswires) -- Gyre Therapeutics ( GYRE ) said late Thursday that the Chinese National Medical Products Administration approved its subsidiary Gyre Pharmaceuticals' investigational new drug application for F230, its therapeutic candidate for pulmonary arterial hypertension. In preclinical studies, F230 showed significant decreases in mean pulmonary arterial pressure, right ventricular systolic pressure, right ventricular/left ventricular plus...
Copyright 2023-2026 - www.financetom.com All Rights Reserved